AMPH vs SUPN vs LNTH vs PCRX

For growth investors, Supernus Pharmaceuticals, Inc.

(SUPN) is the stronger pick with 8. 6% revenue growth year-over-year, versus -1. 7% for Amphastar Pharmaceuticals, Inc. (AMPH). Amphastar Pharmaceuticals, Inc. (AMPH) offers the better valuation at 9. 4x trailing P/E (6. 0x forward), making it the more compelling value choice. Analysts rate Supernus Pharmaceuticals, Inc. (SUPN) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Amphastar Pharmaceuticals, Inc.

(AMPH) is the cheapest at 9. 4x versus Pacira BioSciences, Inc. at 144. 7x. On forward P/E, Amphastar Pharmaceuticals, Inc. is actually cheaper at 6. 0x.

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +338. 1%, compared to -62. 0% for Pacira BioSciences, Inc. (PCRX). Over 10 years, the gap is even starker: LNTH returned +42. 9% versus PCRX's -52. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pacira BioSciences, Inc.

(PCRX) is the lower-risk stock at 0. 41β versus Amphastar Pharmaceuticals, Inc. 's 1. 27β — meaning AMPH is approximately 209% more volatile than PCRX relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 83% for Amphastar Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Supernus Pharmaceuticals, Inc.

(SUPN) is pulling ahead at 8. 6% versus -1. 7% for Amphastar Pharmaceuticals, Inc. (AMPH). On earnings-per-share growth, the picture is similar: Pacira BioSciences, Inc. grew EPS 107. 4% year-over-year, compared to -151. 5% for Supernus Pharmaceuticals, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -5. 4% for Supernus Pharmaceuticals, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -5. 1% for SUPN. At the gross margin level — before operating expenses — SUPN leads at 89. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Amphastar Pharmaceuticals, Inc.

(AMPH) trades at 6. 0x forward P/E versus 20. 8x for Supernus Pharmaceuticals, Inc. — 14. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AMPH: 36. 8% to $26. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lantheus Holdings, Inc.

(LNTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45)). Both have compounded well over 10 years (LNTH: +42. 9%, AMPH: +60. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AMPH is a small-cap deep-value stock; SUPN is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; PCRX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.